Lupus最新文献

{"title":"The role of peritubular capillaritis in severity of lupus nephritis.","authors":"Emel Yaldır, Balça Begüm Cengiz, Mustafa Fuat Açıkalın, Nazife Şule Yaşar Bilge","doi":"10.1177/09612033251335821","DOIUrl":"10.1177/09612033251335821","url":null,"abstract":"<p><p>Background & ObjectivePresence of lupus nephritis is associated with a shorter time to death in systemic lupus erythematosus. The aim of this study was to determine the frequency of peritubular capillaritis (ptc) and its relationship with both active and chronic lesions in lupus nephritis.Material-MethodsSpecimens from 57 patients were re-evaluated. The degree of inflammation within the peritubular capillaries in each biopsy was assessed according to the Banff classification, and ptc scoring was performed. Additionally, patients were grouped based on high/low activity and chronicity index scores.ResultsForty-five (78.9%) of the patients were female, with a mean age of 27.43 years. Ptc was identified in 45 (78.9%) patients, with ptc scores of 1, 2, and 3 observed in 20 (35.08%), 20 (35.08%), and 5 (8.7%) patients, respectively. Severe ptc (scores 2 or 3) was more commonly detected in patients with elevated serum creatinine (>1.20 mg/dL) compared to those with normal creatinine levels (92.3% vs 29.5%, <i>p</i> < 0.001). The severity of ptc was higher in Class 4 patients than in Class 3 patients (68.2% vs 21.7%, <i>p</i> = 0.005). The rate of high ptc scores was greater in patients with an activity index of 6 or above compared to those with an activity index below 6 (62.5% vs 30.3%, <i>p</i> = 0.032). No significant correlation was found between the chronicity index and ptc.ConclusionsThe findings of this study suggest that ptc is a frequently observed pathological feature in patients with lupus nephritis. Furthermore, the severity of ptc appears to be positively associated with elevated serum creatinine levels, and higher ptc scores are more commonly detected in cases with a high activity index.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"742-750"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive repigmentation of hypopigmented lesions in discoid lupus erythematosus with anifrolumab: A report of two cases.","authors":"Margot Hulin, Agathe Le Seac'h, Léa Jaume, Julien Seneschal, Katia Boniface, Annick Barbaud, Alexis Mathian, Zahir Amoura, François Chasset","doi":"10.1177/09612033251345017","DOIUrl":"10.1177/09612033251345017","url":null,"abstract":"<p><p>We report two cases of patients with refractory discoid lupus erythematosus (DLE) and dark skin phototypes who experienced progressive perifollicular repigmentation of depigmented lesions under anifrolumab therapy, with sustained improvement over 18 months. These observations highlight a potential novel effect of anifrolumab on cicatricial dyspigmentation in DLE. This effect may represent a valuable therapeutic option for DLE-related damage, particularly in patients with darker skin types.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"761-763"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical significance of anti-lipoprotein lipase antibodies in Japanese patients with systemic lupus erythematosus.","authors":"Taro Horino, Takeshi Kashio, Satoshi Inotani, Yoshio Terada","doi":"10.1177/09612033251344051","DOIUrl":"10.1177/09612033251344051","url":null,"abstract":"<p><p>ObjectivesAs there is a lack of reports on the association between anti-lipoprotein lipase (anti-LPL) antibodies and dyslipoproteinemia, we aimed to analyse the association between anti-LPL antibodies and the clinical and serological characteristics of patients with systemic lupus erythematosus (SLE) and cardiovascular (CV) events.MethodsEighty patients with SLE were examined for the presence of anti-LPL antibodies via western blotting. Data on laboratory findings and the occurrence of CV events were retrospectively collected and evaluated. Patients with SLE were classified into two groups according to the detection of anti-LPL antibodies: anti-LPL antibody-positive and antibody-negative.ResultsAnti-LPL antibody immunoglobulin G was detected in 28 patients with SLE (35.0%). Additionally, triglyceride levels tended to be higher in the anti-LPL antibody-positive group than in the anti-LPL antibody-negative group. The former exhibited significantly higher levels of serum albumin, anti-Smith antibody, and IgM than the latter. The incidence of CV events was higher in the anti-LPL antibody-positive group than in the anti-LPL antibody-negative group (35.7% vs 5.8%, <i>p</i> = .001). Additionally, the risk of CV events was significantly higher in the anti-LPL antibody-positive group, with a hazard ratio of 169.20 (95% confidence interval: 5.75-4981.54, <i>p</i> = .003).ConclusionIn this study, the positivity rate of anti-LPL antibodies was high among Japanese patients with SLE. Additionally, a significantly higher incidence of CV events was observed in the anti-LPL antibody-positive group compared to that in the anti-LPL antibody-negative group.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"699-704"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chorea associated with systemic lupus erythematosus- a systematic review.","authors":"Paulo Rogério Julio, Carla Helena Capello, Jaqueline Cristina de Amorim, Samuel de Oliveira Andrade, Laura Silveira-Moriyama, Ana Carolina Coan, Simone Appenzeller","doi":"10.1177/09612033251344045","DOIUrl":"10.1177/09612033251344045","url":null,"abstract":"<p><p>ObjectiveChorea is one of the 19 neuropsychiatric manifestations observed in systemic lupus erythematosus (SLE). This article reviews the literature to determine the prevalence and clinical and laboratory features associated with chorea in SLE.MethodsWe performed a literature review following the PRISMA guidelines and using the following MESH terms in the search and analysis: \"Chorea\", \"movement disorders\", \"systemic lupus erythematosus\", \"SLE\", \"neuropsychiatric manifestations\", \"neuropsychiatric lupus (NPSLE)\", with full articles in English, Portuguese, and Spanish, between September 1999 and January 2024, in PubMed and Scielo.Results13,922 patients from 60 cohort studies and 41 patients from 18 case/series reports were included. Chorea had a pooled prevalence of 1.1% in SLE patients. We found no association between chorea and clinical or immunological features reported in cohort studies. In case series and case reports, chorea occurred more frequently before or at SLE diagnosis and more frequently in childhood-onset SLE. We propose an investigation and treatment scheme based on the literature review.ConclusionChorea is a rare manifestation in SLE and factors associated with its occurrence have not been addressed in cohort studies.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"687-698"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between excess body weight and disordered eating attitude among women living with systemic lupus erythematosus.","authors":"Jhulia Cnl da Mota, Fabiana I Smaira, Juliana Maria Gonçalves Julio, Beatriz Garcia de Carvalho, Lucas M Carvalho, Amanda A Ribeiro, Leticia L Souza, Eduardo F Borba, Hamilton Roschel, Bruno Gualano, Carolina F Nicoletti","doi":"10.1177/09612033251332830","DOIUrl":"10.1177/09612033251332830","url":null,"abstract":"<p><p>The study aimed to: (i) characterize dietary intake and identify disorders eating attitudes in women with SLE, (ii) evaluate possible differences in both dietary intake and disorders eating attitudes in patients with SLE according to nutritional status, (iii) investigate possible associations between eating disorders attitudes, anthropometric characteristics and food consumption.</p><p><strong>Methods: </strong>This cross-sectional study included 46 premenopausal female patients (18-40 years), with inactive disease, using prednisone <10 mg/day and hydroxychloroquine at a stable dose. Patients were allocated into two groups according to their nutritional status by body mass index (BMI): normal weight (BMI between 18.5 and 24.9 kg/m²) and excess weight (BMI >25 kg/m²). Food consumption was assessed according to the processing level and energy and macronutrient content. The Disordered Eating Attitude Scale (DEAS) was applied.</p><p><strong>Results: </strong>Patients with excess weight had a higher DEAS score when compared to those with normal weight (34 ± 8.7 vs 25 ± 5.9, <i>p</i> = .001). A higher percentage of patients with excess weight demonstrated disturbance in their relationship with food and concerns about food and weight gain versus those with normal weight. DEAS score was positively associated with BMI, abdominal circumference, and fat mass percentage and negatively associated with lipid intake.</p><p><strong>Conclusion: </strong>Disordered eating attitudes differ in SLE patients according to nutritional status, and those with excess weight show higher DEAS scores, which may be related to food and weight gain.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"657-665"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baby you can drive my CAR-T cells.","authors":"Daniela Garelick, David A Isenberg","doi":"10.1177/09612033251335798","DOIUrl":"10.1177/09612033251335798","url":null,"abstract":"<p><p>ObjectiveTo evaluate the potential of chimeric antigen receptor T-cell (CAR-T) therapy in revolutionizing the treatment of systemic lupus erythematosus (SLE) and to outline necessary future steps for its implementation.MethodsA careful literature search was conducted for relevant English language papers on pubmed.ResultsPreliminary data suggest that CAR-T therapy could significantly improve SLE outcomes. Demonstrating remarkable clinical and serologic improvements in SLE patients, with all treated patients achieving remission and discontinuing conventional steroids and immunosuppressive drugs. To realize this potential, it is imperative to advance our understanding and application of CAR-T therapy. Rigorous research is necessary to validate current findings, and clinical trials must be conducted to assess both the short- and long-term efficacy and safety across diverse populations. Identifying appropriate patient populations is crucial, as CAR-T may also address compliance issues. Despite its current high cost, the financial burden is comparable to the long-term costs of severe SLE treatment. Strategies to reduce costs, including production efficiencies and outpatient treatment options, are under exploration. Early intervention could enhance its feasibility and impact on long-term prognosis.ConclusionCAR-T therapy holds promise for altering the prognosis of SLE and potentially offering a cure. However, substantial efforts are required to validate its efficacy, ensure safety, identify suitable patient cohorts, and reduce financial barriers. This development represents an exciting advancement in SLE treatment, necessitating urgent and focused research and clinical application.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"653-656"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe gastrointestinal manifestations in childhood-onset lupus: A single-center cohort and review of the literature.","authors":"James Orozco, Jessica Nguyen, Sara Mm Yasrebi, Marnie Blalock, Sara L Grisales, Craig L Jensen, Marietta M DeGuzman","doi":"10.1177/09612033251345020","DOIUrl":"10.1177/09612033251345020","url":null,"abstract":"<p><p>ObjectiveSystemic lupus erythematosus (SLE) is a complex autoimmune condition with diverse manifestations. Childhood-onset SLE (cSLE) presents more severely than adult-onset disease with a higher incidence of severe neurologic or renal manifestations and lower estimated survival rates. There is limited literature on the range of severe gastrointestinal manifestations at presentation in cSLE, and this lack of information results in underappreciation of these potentially life-threatening complications and little guidance regarding management of these patients.MethodsWe reviewed cases of patients with cSLE and severe GI manifestations at presentation diagnosed at our institution and additionally provide a comprehensive review of existing cases in the literature to discuss presenting symptoms, other clinical features, longitudinal course, treatment, and long-term outcomes.ResultsWe identified six cases of cSLE with primary, severe GI symptoms at time of diagnosis at our institution and an additional 25 patients who presented similarly in the literature. Severe GI manifestations included protein-losing enteropathy, thoracoabdominal aortitis, severe pancreatitis, lupus enteritis or mesenteric vasculitis, and intestinal pseudo-obstruction. Delays in diagnosis affected several patients, and 26% of patients required surgical intervention. Many patients required intensive immunomodulatory treatment in addition to prolonged bowel rest and parenteral nutrition. Long-term outcomes of GI manifestations varied overall, however, most patients at our institution achieved clinical remission.ConclusionsUnderstanding these rare cases of severe GI manifestations in cSLE can aid clinicians in prompt diagnosis and collaborative management, improving clinical outcomes for this vulnerable population.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"721-741"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of carotid intima-media thickness and cognitive function in systemic lupus erythematosus patients versus healthy subjects.","authors":"Uni Gamayani, Syarief Hidayat, Chandra Calista, Paulus Anam Ong, Hans Albertus, Isga Ifayani, Muhammad Arsyi, Vilya Rizkianti Alita, Sasfia Candrianita, Mas Rizky Aa Syamsunarno, Kevin Karim, Laniyati Hamijoyo","doi":"10.1177/09612033251344167","DOIUrl":"10.1177/09612033251344167","url":null,"abstract":"<p><p>BackgroundSystemic Lupus Erythematosus (SLE) patients tend to have accelerated atherosclerosis. It mayhave a role in the impairment of cognitive function related to a decrease in cerebrovascular blood flow.MethodsSixty SLE patients and 61 healthy subjects as participants underwent: history taking, physicalexamination, blood examination, medication, carotid Doppler ultrasound test, and cognitive function test.We compared Carotid Intima-media Thickness (CIMT) and Montreal Cognitive Assessment IndonesianVersion (MoCA-Ina) scores of the two groups.ResultThe comparison of the total MoCA-Ina scores between the two groups was not statistically significant (<i>p</i> = .332). However, the orientation domain in the SLE group was statistically lower than the HS group (5.83 ± 0.41 vs 6 ± 0.00, <i>p</i> = .002). The SLE group was found to have a thicker anterior and posterior IMT of right carotid artery (<i>p</i> < .001, <i>p</i> = .031) and a thicker anterior IMT of left carotid artery (<i>p</i> < .001). There was a significant inverse correlation between the total MoCA-Ina score and the posterior IMT of the left carotid artery (r = -0.272, <i>p</i> = .035) of SLE patients. Atherosclerosis plaque of the right carotid artery was not associated with total MoCA-Ina score; however, there was a significant association with the attention domain (<i>p</i> = .023) and the visuospatial domain of MoCA-Ina (<i>p</i> = .018).ConclusionSLE patients have lower orientation domain of MoCA-Ina and thicker CIMT than healthy subjects. Atherosclerosis plaque of the carotid artery was associated with attention and visuospatial domains of MoCA-Ina.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"713-720"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversible dilated cardiomyopathy in systemic lupus erythematosus: A case report.","authors":"Jorge Reis, Marta Leite, Guilherme Jesus, Diogo Ferreira, Sofia Pereira, Andreia Seixas","doi":"10.1177/09612033251337516","DOIUrl":"10.1177/09612033251337516","url":null,"abstract":"<p><p>A 40-year-old woman presented with new-onset heart failure with reduced ejection fraction (HFrEF) accompanied with systemic symptoms, including arthralgia, cutaneous lesions, and Raynaud's phenomenon. Initial investigation led to the diagnosis of systemic lupus erythematosus (SLE), with subsequent finding of dilated cardiomyopathy, a rare but severe secondary manifestation of SLE. Early recognition and appropriate management of underlying autoimmune conditions can lead to substantial improvement in cardiac function, emphasizing the need for comprehensive evaluation in patients with <i>de novo</i> heart failure and systemic symptoms.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"757-760"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infection vulnerability in pregnant women with and without systemic lupus erythematosus.","authors":"Hiba I Khogali, Aaesha M Alhebsi, Meera A Altamimi, Ghada Sm Al-Bluwi, Virgie Guy Pedo, Ali M Al Dhanhani","doi":"10.1177/09612033251344195","DOIUrl":"10.1177/09612033251344195","url":null,"abstract":"<p><p>ObjectiveSystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that predominantly affects females. SLE poses risks to the mother and fetus during pregnancy. Information on infection rates during pregnancy in patients with SLE is scarce. Therefore, this study assessed infection risk during pregnancy in women with and without SLE, and identified the factors influencing susceptibility to infections.MethodsWe conducted a retrospective cohort analysis using medical records from Tawam Hospital, Abu Dhabi, United Arab Emirates. Emirati women diagnosed with SLE who experienced one or more pregnancies between January 2010 and August 2023 were included in the study. Patients with SLE were compared with an age-matched control group of women without SLE. The control group was systematically selected from the hospital records of the same period. Demographic details, clinical data, and comprehensive infection histories during and before pregnancy were examined. Univariate and multivariate regression analyses were used to identify the factors contributing to the risk of infection in pregnant women with SLE.ResultsData from 87 pregnancies in 41 women with SLE were analyzed. The mean age at conception was higher in women with SLE compared to the control group. The rates of infections (54.7% vs 29.8%), adverse fetal outcomes (48.3% vs 24.2%), and maternal outcomes (71.3% vs 43%) were significantly higher in the SLE group than in the control group. Respiratory infections were the most prevalent infection type. No variable was found to increase the risk of infection; however, hydroxychloroquine use during pregnancy was significantly associated with a reduced risk of infection.ConclusionsThe risks of infection and adverse outcomes are significantly higher in pregnant women with SLE than in the non-SLE population. Hydroxychloroquine use during pregnancy was crucial in reducing infection risk. These findings underscore the need for targeted interventions and a multidisciplinary care approach to improve pregnancy outcomes in women with SLE.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"705-712"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}